Ototoxic side effects of cisplatin and aminoglycosides have been extensively studied, but 14 no therapy is available to date. Sensory hair cells, upon exposure to cisplatin or 15 aminoglycosides, undergo apoptotic and necrotic cell death. Blocking these cell death 16 pathways has therapeutic potential in theory, but incomplete protection and lack of 17 therapeutic targets in the case of necrosis, has hampered the development of clinically 18 applicable drugs. Over the past decade, a novel form of necrosis, termed necroptosis, was 19 established as an alternative cell death pathway. Necroptosis is distinguished from passive 20 necrotic cell death, in that it follows a cellular program, involving the receptor-interacting 21 protein kinases 1 and 3 (RIPK1 and 3). In this study, we used pharmacological and genetic 22 intervention to test the relative contributions of necroptosis and caspase-8-mediated 23 apoptosis towards cisplatin and aminoglycoside ototoxicity. We find that ex vivo, only 24 apoptosis contributes to cisplatin and aminoglycoside ototoxicity, while in vivo, both 25 necroptosis and apoptosis are involved. Inhibition of necroptosis and apoptosis using 26 pharmacological compounds is thus a viable strategy to ameliorate aminoglycoside and 27 cisplatin ototoxicity.
Introduction

48
The clinical application of the chemotherapeutic agent cisplatin, used in the treatment of 49 various types of solid tumors (Einhorn, 2002; Burdett et al., 2015) , is dose-limited due to 50 nephrotoxicity and ototoxicity (Karasawa and Steyger, 2015) . Cisplatin results in the death 51 of sensory hair cells, but the underlying mechanisms are still poorly understood (Sheth et 160 161 Mice were killed after the final ABRs. Cochleae were dissected, openings were created at 162 the base and apex of the cochlea and fixed in 4% paraformaldehyde (PFA) (RT-15720, 163 Electron Microscopy Science, PA) for 24h. After decalcification for 7 days in EDTA 164 solution, all turns of the cochlear sensory epithelium were dissected. Hair cell counting was 165 performed for the organ of Corti using Myo7a immunoreactivity as a marker of hair cell 166 presence. After confocal microscopy, images were analyzed using ImageJ. Hair cells were 167 counted from the apical (0.5-1 mm from apex tip, corresponding to the 6-8 kHz region), 168 mid (1.9 -3.3 mm from the apex tip, corresponding to 12-24 kHz region) and basal turns 169 (4.7-5.5 mm from the apex tip, corresponding to 48-64 kHz region) of the cochlea. Hair For statistical analysis, GraphPad Prism (La Jolla, CA) was used. One-way analysis of 178 variance (ANOVA) was used to determine statistically significant differences between the 179 means of the experimental groups. For pair-wise comparisons, a Tukey post-hoc analysis 180 was performed. P-values smaller than 0.05 were considered statistically significant. All n 181 in statistical analyses refer to number animals (for in vivo experiments) and organs of Corti 182 (for ex vivo experiments). All error bars indicate standard deviation (SD). Mouse model for cisplatin-mediated hearing loss 185 186 To elicit cisplatin-induced hearing loss in the mouse, we followed a protocol established 187 by Li et al. (Li et al., 2011) . Mice were injected with 200 mg/kg body weight with the loop 188 diuretic furosemide. 1 h later, cisplatin was injected intraperitoneally (i.p.) at a 189 concentration of 1 mg/kg body weight, in a total of 1 ml saline. This was repeated daily for 190 a total of 3 days. Control mice were injected with vehicle (saline or DMSO/saline mix) 191 only. In groups treated with Nec-1s, the drug was injected i.p. one hour prior to treatment 192 with cisplatin. Our standard dose of 3 mg/kg Nec-1s was chosen from a priori protocols 193 with dosing schedules ranging from 1.2 mg/kg to 5mg/kg (Tristão et al., 2016; Wang et al., 194 2017). 195 196 Mouse model for kanamycin-mediated hearing loss 197 198 To elicit kanamycin-induced hearing loss in the mouse, we followed a 199 furosemide/kanamycin combination protocol (Taylor et al., 2008) . Mice were injected with 200 one i.p. injection of 600 mg/kg of Kanamycin followed one hour later by an i.p. dose of 201 400 mg/kg of furosemide. In treatment groups treated with Nec-1s (3 mg/kg or 0.3 mg/kg), 202 the drug was injected in an i.p. fashion one hour before treatment with kanamycin.
Hair cell counts from in vivo experiments
204
Auditory Brainstem Response (ABR) Testing 205 206 ABR testing was performed on each mouse before initiation of drug treatment, 48 hours 207 post-kanamycin treatment, 10 days post-cisplatin treatment, and 2 weeks following initial 208 posttreatment ABR. Anesthesia with a single intraperitoneal injection of Ketamine at 100 209 mg/kg was performed prior to testing. The mouse was then placed on a Deltaphase 210 isothermal warming pad (Braintree Scientific) and subdermal needle electrodes 211 Grass Technologies) were inserted as follows: (1) reference electrode was inserted in the 212 mastoid area of the right ear, (2) the active electrode was inserted at the vertex of the scalp,
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(3) the ground electrode was inserted in the left gluteus. The relative contribution of apoptosis and necrosis to drug-induced hair cell death was 235 reported to differ between ex vivo and in vivo experimental contexts (Forge and Schacht, 236 2000; Jiang et al., 2006; Rybak et al., 2006) . For a comprehensive appreciation of the role 237 of necroptosis and apoptosis in aminoglycoside and cisplatin ototoxicity, we therefore 238 performed both ex vivo and in vivo experiments. Necrostatin-1s (Nec-1s) is a selective 239 inhibitor of receptor-interacting protein kinase RIPK1, which in conjunction with RIPK3, 240 are the principal mediators of necroptosis (Weinlich et al., 2017) . We first conducted a were comparable to vehicle-treated controls, suggesting that inhibition of RIPK1-mediated 249 necroptosis had no effect on hair cells (Figure 1A) , and failed to provide any protection 250 from cisplatin and kanamycin induced hair cell death ex vivo (Figure 1B, C) . We next Next, we tested the otoprotective potential of Nec-1s in vivo. Previous studies had shown 266 that, in contrast to ex vivo cultures, both apoptosis and necrosis contribute to ototoxicity in 267 vivo (Jiang et al., 2006) . We thus hypothesized that in vivo, necroptosis might contribute 268 significantly to kanamycin and cisplatin-mediated ototoxicity. We first tested whether Nec-269 1s treatment protects against kanamycin ototoxicity in the mouse. Auditory brainstem 270 responses (ABRs) were measured 1 day prior to administration of drugs (pre-exposure 271 ABRs). Nec-1s (3 or 0.3 mg/kg body weight) was administered i.p., followed 1 hour later 272 with a mix of kanamycin and loop diuretics (Figure 2A) . Post-exposure ABRs were 273 measured 2 days after drug administration, after which mice were killed and processed for 274 hair cell counts. In contrast to ex vivo, RIPK inhibition by Nec-1s provided significant Figure 2E shows the relative ABR threshold difference (shift) between pre-282 and post-ABRs. In mice that were additionally treated with 3 mg/kg Nec-1s, the thresholds 283 increased only to ~40-50 dB across tested frequencies, representing an improvement of 284 threshold shift by an average of ~30 dB in this group (Figure 2C, E) . When Nec-1s was 285 administered at a 10-fold diluted concentration, the protective effect was lost, 286 demonstrating a dose-dependent protection of Nec-1s in vivo (Figure 2D, E) . To test 287 whether the protective effect of Nec-1s was maintained after withdrawal of the drug, we 288 determined ABR thresholds 14 days (D14) after Nec-1s administration. The improvement 289 in hearing threshold in the Nec-1s treated group was maintained at day 14 ( Figure 2F) , 290 suggesting the beneficial effect of Nec-1s for hearing function persisted after its withdrawal.
291
It should be noted that the ototoxin kanamycin was also absent during this time period. We 292 conclude that in vivo, necroptosis contributes significantly to kanamycin-induced hearing 293 loss.
295 296
Pharmacological blockade of RIPK1 protects against cisplatin-induced hair cell death 297 in vivo 298 299 We next tested whether Nec-1s also alleviates cisplatin-induced ototoxicity in vivo. ABRs 300 were tested 1 day prior to administration of drugs (pre-exposure ABRs). Nec-1s (3 or 0.3 301 mg/kg body weight) was administered i.p., followed 1 hour later with a mix of cisplatin 302 with a loop diuretic (furosemide) ( Figure 3A) . This was repeated daily for 3 days. Post-303 exposure ABRs were measured 10 days after the completion of drug administration, after 304 which mice were killed and processed for hair cell counts. Similar to the results for 305 kanamycin ototoxicity, administration of 3 mg/kg Nec-1s provided significant protection 306 from ototoxic hearing loss. ABR thresholds improved an average of ~30 dB across all 307 tested frequencies in the Nec-1s treated group (Figure 3B, C, E) . When Nec-1s was 308 administered at a 10-fold diluted concentration, the protective effect was again lost, and 309 hearing thresholds reverted to values similar to WTs exposed to cisplatin (Figure 3D, E) . 310 The Figures 3B-D indicate ABR thresholds, while the summary plot in Figure 3E shows 311 the ABR threshold shifts between pre-and post-ABRs. To test whether the protective effect 312 of Nec-1s was maintained after withdrawal of the drug, we performed a separate 313 experiment in which ABR thresholds were determined 24 days (D24) (initial post-exposure 314 ABRs at D10) after Nec-1s administration. The hearing benefit in the Nec-1s treated group 315 was maintained up to 24 days, while the hearing thresholds without Nec-1s treatment even 316 worsened between 10 days and 24 days after cisplatin treatment (Figure 3F ), suggesting 317 the beneficial effect of nec-1s for hearing function persisted after its withdrawal.
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Taken together, we conclude that the effect of Nec-1s mediated inhibition of necroptosis 319 differs starkly between in vivo and ex vivo experiments, and that in vivo, pharmacological Next, we used genetic mouse models to assess the relative contributions of RIPK3 and 326 Caspase-8 in kanamycin and cisplatin ototoxicity in vivo. We decided to make use of mice 327 that harbor single mutations in the Ripk3 gene or combined null mutations in the Ripk3 and Prior to exposing the mice to the ototoxicity paradigms, we first ascertained that the 344 Ripk3/Casp8 DOKO mice have normal hearing function. We performed a longitudinal 345 hearing function study, testing ABRs at 8, 11, 14 and 20 weeks of age in Ripk3/Casp8 346 DOKO and WT controls and found no significant differences between the two groups 347 (Figure 4 A-D) . We also tested whether the lack of Caspase-8 might affect the apoptosis 348 of cells in the Kolliker's organ between postnatal days 7 and 13, thought to contribute to 349 the remodeling of the greater epithelial ridge during postnatal development (Hinojosa, 350 1977; Knipper et al., 1999; Kamiya et al., 2001) . Counting caspase-3 positive cells in the 351 Kolliker's organ at P8 did not reveal any differences between Ripk3/Casp8 DOKO and WT 352 controls (Fig 4.E, F) . We conclude that Ripk3/Casp8 DOKO mice have a likely normal 353 cochlear development and normal hearing function up to 20 weeks of age.
355
Genetic inhibition of RIPK3 and Caspase-8 alleviates kanamycin ototoxicity in vivo 356 357 We next tested whether Ripk3 single KO mice and Ripk3/Casp8 DOKO mice are protected 358 from kanamycin ototoxicity in vivo. Mice were exposed to the same kanamycin ototoxicity 359 protocol used for the Nec-1s inhibitor studies (Figure 5A) . When WT mice were exposed 360 to kanamycin, the hearing thresholds increased by ~50-60 dB compared to pre-exposure 361 ABR thresholds, affecting all frequencies in a comparable manner (Fig 5. B, E) . The presented with ABR thresholds that were significantly improved compared to WT mice, 365 with thresholds shifting 2 days after kanamycin exposure by only ~30 dB in average 366 9 (Figure 5C, E) . Ripk3/Casp8 DOKO mice were protected most, with ABR thresholds 367 shifting by only ~15-20 dB after kanamycin exposure (Figure 5D, E) , indicating that 368 combined deletion of RIPK3-mediated necroptosis and Caspase-8 mediated apoptosis 369 alleviates kanamycin ototoxicity in an additive manner.
371
Genetic inhibition of RIPK3 and Caspase-8 alleviates cisplatin ototoxicity in vivo 372 373 We next tested whether Ripk3 single KO mice and Ripk3/Casp8 DOKO mice are protected 374 from cisplatin ototoxicity in vivo. Mice were exposed to the cisplatin ototoxicity protocol 375 used for the Nec-1s inhibitor studies (Figure 6A) . WT mice exposed to cisplatin presented 376 with hearing thresholds of ~60-70 dB, which constitutes a shift of ~40-50 dB compared to 377 pre-exposure ABRs. All frequencies were affected in a comparable manner (Fig 6B, E) .
378
Ripk3 KO mice presented with hearing thresholds of ~40-50 dB, which constitutes a shift 379 of only 15-20 dB compared to pre-exposure ABRs, thus were significantly improved 380 compared to WT mice (Figure 6C, E) . Ripk3/Casp-8 DOKO mice experienced the most 381 pronounced protection, with ABR thresholds shifting by only ~10 dB after cisplatin 382 exposure (Figure 6D, E) . This indicates that combined deletion of RIPK3-mediated 383 necroptosis and Caspase-8 mediated apoptosis alleviates cisplatin ototoxicity in an additive 384 manner.
386
The otoprotective effect of inhibiting RIPK3-mediated necroptosis and Caspase-8 387 mediated apoptosis correlates with improved hair cell survival.
389
If the improved hearing performance in mice treated with Nec-1s or deficient for Ripk3 390 and/or Casp8 is mediated by inhibition of necroptotic and/or apoptotic cell death, it should 391 be reflected in improved hair cell survival. We tested this by counting cochlear hair cells 392 from all experimental groups. Hair cell counts were performed from the apical (0.5-1 mm 393 from apex tip, corresponding to the 6-8 kHz region), mid (1.9-3.3 mm from the apex tip, 394 corresponding to 12-24 kHz region) and basal turns (4.7-5.5 mm from the apex tip, 395 corresponding to 48-64 kHz region) of the cochlea. In WT mice exposed to kanamycin, 396 inner hair cells in the apical and mid regions were mostly unaffected, but basal inner hair 397 cells were significantly reduced in numbers (IHC counts ~80% lower compared to 398 unexposed control mice) (Figure 7A, C) . IHCs in Ripk3 single KO and Ripk3/Casp8 399 DOKO mice, and mice treated with Nec-1 maintained most IHCs, with minor (10-20%) 400 losses reported at basal regions compared to untreated controls (Figure 7A, C) . OHC 401 numbers were much more affected by kanamycin exposure: In WT mice exposed to 402 kanamycin, virtually all OHCs were lost (Figure 7A, B) . Ripk3 single KO mice showed 403 improved hair cell survival, and the OHCs of Ripk3/Casp8 DOKO mice were most 404 protected (Figure 7A, B) . Nec-1s treated mice showed some protection but did not reach 405 the level of Ripk3 KO mice (Figure 7A, B) . 406 In the cisplatin treated group, inner hair cells were not affected at all, in all mouse 407 genotypes (no quantification shown), while OHCs were affected in a genotype-dependent 408 manner (Figure 7D, E) . In WT mice exposed to cisplatin, OHC numbers were reduced by 409 ~30, 50 and 70 % (apex, mid, base) compared to untreated controls (Figure 7D, E) . Ripk3 410 single KO mice showed improved hair cell survival, retaining most hair cells at apical and 411 mid turns, but loosing ~30% at the base (Figure 7D, E) . OHC counts in Ripk3/Casp8 412 10 DOKO mice were similar to the single KO at the apex and mid, but were better at the base 413 ( Figure 7D, E) . Nec-1s treated mice showed some protection compared to WT mice but 414 did not reach the level of Ripk3 KO mice (Figure 7D, E) . In summary, we conclude that 415 the otoprotective effect of inhibiting RIPK3-mediated necroptosis and Caspase-8 mediated 416 apoptosis correlates with improved hair cell survival. Necroptosis is executed by RIPK1 and RIPK3 when apoptosis-mediating caspases are 422 inhibited (Yuan et al., 2016) . Due to this compensatory interplay between the cell death 423 pathways, necroptosis and apoptosis are best studied in mutual context. We achieved this 424 by studying the ototoxic response of mouse models in which RIPK3-mediated necroptosis, 425 and/or Caspase-8 mediated apoptosis is disrupted. In addition, we tested the ex vivo and in 426 vivo efficiency of the small-molecule inhibitor of RIPK1 Nec-1s.
427
Historically, both ex vivo and in vivo studies have provided important insights into the 428 mechanisms underlying hair cell death pathways (Wu et al., 2001; Wang et al., 2004; 429 Rybak, 2007; Rybak et al., 2007; Guthrie, 2008; Warchol, 2010; Ding et al., 2011; Schacht 430 et al., 2012; Francis et al., 2013; Nicholas et al., 2017) . The conclusions, however, differ 431 significantly between the ex vivo and in vivo context, and thus have created confusion in 432 the ototoxicity field. Inconsistencies possibly arise from differences in age (usually P3-4 433 ex vivo, and adult mice for in vivo experiments), the denervation of hair cells and absence 434 of endolymph and strial environment in the ex vivo context, to name just the most salient 435 differences. In general, apoptotic cell death was more frequently implicated in ex vivo 436 studies, while a mix of apoptotic, necrotic and caspase-independent cell death was 437 implicated in in vivo studies (Forge and Schacht, 2000; Jiang et al., 2006; Rybak et al., 438 2006) . This is in good agreement with our present study: in our ex vivo experiments, two 439 lines of evidence suggest that necroptosis is not involved in hair cell death: First, addition 440 of the necroptosis inhibitor Nec-1s had no effect on hair cell survival, neither in the 441 unstressed nor kanamycin-and cisplatin-exposed explants. Furthermore, the pan-caspase be attributed to caspase-mediated apoptosis. This is in agreement with a multitude of 448 previous studies (Forge and Schacht, 2000; Cheng et al., 2005; Jiang et al., 2006; Rybak et 449 al., 2006; Rybak and Ramkumar, 2007; Huth et al., 2011; Schacht et al., 2012; Sheth et al., 450 2017) . In vivo, however, our study found that both necroptosis and apoptosis contribute to 
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In our study, hearing rescue correlates with improved hair cell survival, which is consistent 482 with the hypothesis that hair cells are the mediators of ototoxicity and otoprotection.
483
However, it is also possible that the benefit of necroptosis and apoptosis inhibition is not 484 mediated by hair cells, and that the improvement of hair cell survival is a secondary effect, 485 possibly by protection of other cell types such as strial cells. This is especially relevant 486 considering the fact that the ototoxicity protocols used in this study, utilizing loop diuretics 487 to increase penetration of ototoxins through the blood-labyrinth barrier, is known to cause 488 additional damage to the stria vascularis (Hirose and Sato, 2011) . The question of the 489 primary target cell type of cisplatin and aminoglycoside ototoxicity needs to be addressed 490 in cell-type specific studies using conditional KO mice.
492
In contrast to apoptosis characterized by its traceless removal of dead cells, necroptosis, 493 due to release of intracellular components acting as damage-associated molecular patterns 494 (DAMPs) in the extracellular space, creates an inflammatory response, which is often 495 beneficial for resolving the insult. A hair cell with necroptotic response thus would only 496 make sense if the inner ear was not "immune privileged" as historically assumed but was 497 capable of mounting a significant immunological response. In fact, more recent studies 498 suggest that the resolution of ototoxic insults is aided by immune cells infiltrating into the 499 inner ear (Kaur, 2015; Kaur et al., 2015 Kaur et al., , 2018 Francis and Cunningham, 2017; Mizushima 500 et al., 2017; Wood and Zuo, 2017; Barald et al., 2018; Liu et al., 2018) . Such immune 501 activity, beneficial under normal circumstances, might become counterproductive when 502 ototoxins overwhelm the system, creating a massive, detrimental immune response. With 503 the potential involvement of the immune response in ototoxicity, the interpretation of our 504 study is complicated by another connection to the neuro-immune angle: RIPK3, previously 505 exclusively implicated in necroptosis, was also shown to be important for inflammatory 506 signaling (Daniels et al., 2017) . Ripk3 KO mice thus might have aberrant inflammatory 507 signaling that might modify, in a positive or negative manner, the otoprotection provided 508 by the inhibition of necroptotic hair cell death. A potential role of RIPK3 in ototoxicity 509 independent from its role in necroptotic cell death could be explored using mice that are 510 deficient in other mediators of necroptosis, such mixed lineage kinase domain-like 511 protein MLKL, which is a downstream effector of RIPK3 (Cho et al., 2009; Wang et al., 512 2014).
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It should be noted that the protection provided by the genetic inhibition of RIPK3-mediated 
